https://www.globenewswire.com/news-release/2026/03/31/3266139/0/en/Aptose-Biosciences-Announces-Results-of-Special-Shareholders-Meeting-Announces-Receipt-of-Final-Court-Approval-of-Plan-of-Arrangement-Reports-Year-End-2025-Results-and-Corporate-Hi.html
Aptose Biosciences Announces Results of Special
Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End...
biosciencesannouncesresultsspecial
https://www.nasdaq.com/market-activity/stocks/apto/advanced-charting
Aptose Biosciences Inc. (APTO) Advanced Charting | Nasdaq
Aptose Biosciences Inc. (APTO) interactive stock charts, quotes, and comparrisons for US and global markets. No one knows the market like Nasdaq.
advanced chartingbiosciencesincaptonasdaq
https://markets.businessinsider.com/news/stocks/aptose-selected-for-prestigious-oral-presentation-of-data-from-tuscany-phase-1-2-clinical-trial-of-tuspetinib-triplet-therapy-in-newly-diagnosed-aml-at-the-2025-eha-congress-1034723296
Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of...
Aptose is developing TUS+VEN+AZA as a one-of-a-kind safe and mutation agnostic frontline triple drug therapy for newly diagnosed AMLOral presentat...
https://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-motus-gi-aurinia-pharmaceuticals-aptose-biosciences-vaxart-or-atossa-therapeutics-301281193.html
Thinking about buying stock in Motus GI, Aurinia Pharmaceuticals, Aptose Biosciences, Vaxart, or...
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MOTS, AUPH, APTO, VXRT, and ATOS. To see how InvestorsObserver's proprietary scoring...
thinking about buying
https://www.benzinga.com/25/02/43859672/why-is-penny-stock-aptose-biosciences-trading-higher-on-thursday
Why Is Penny Stock Aptose Biosciences Trading Higher On Thursday? - Benzinga
Feb 20, 2025 - Aptose Biosciences advances its Phase 1/2 TUSCANY trial, escalating tuspetinib dosing after a favorable safety review. Enrollment continues across U.S. sites.
penny stockon thursday